| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/27/2001 | US6207686 Endothelin antagonists |
| 03/27/2001 | US6207663 Vitronectin receptor antagonists, their preparation and use |
| 03/27/2001 | US6207660 Texaphyrin conjugates and uses thereof |
| 03/27/2001 | US6207656 Treating neurodegenerative diseases or disorders by administering low calcemic vitamin d analog compound |
| 03/27/2001 | CA2201098C Orphan receptor |
| 03/27/2001 | CA2065860C Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix |
| 03/27/2001 | CA2033771C Indolylpropanols, process for their preparation and their use and preparations containing the compounds |
| 03/22/2001 | WO2001020031A2 Polymorphisms in a klotho gene |
| 03/22/2001 | WO2001019986A1 Peptide leukotriene receptor |
| 03/22/2001 | WO2001019983A1 Human g-protein coupled receptor |
| 03/22/2001 | WO2001019977A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 03/22/2001 | WO2001019868A1 A novel angiogenesis inhibitor |
| 03/22/2001 | WO2001019860A2 Proteins associated with cell differentiation |
| 03/22/2001 | WO2001019839A1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| 03/22/2001 | WO2001019829A2 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | WO2001019828A2 Kinase inhibitors as therapeutic agents |
| 03/22/2001 | WO2001019826A2 Triazolopyrimidine derivatives |
| 03/22/2001 | WO2001019825A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | WO2001019823A2 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 03/22/2001 | WO2001019816A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 03/22/2001 | WO2001019814A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | WO2001019802A1 Aromatic nitrogenous six-membered ring compounds |
| 03/22/2001 | WO2001019795A1 Azacycloalkanone serine protease inhibitors |
| 03/22/2001 | WO2001019790A1 Prostaglandin derivatives |
| 03/22/2001 | WO2001019789A1 Prostaglandin derivatives |
| 03/22/2001 | WO2001019788A2 BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| 03/22/2001 | WO2001019780A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 03/22/2001 | WO2001019778A1 Novel dicarboxylic acid derivatives with pharmaceutical properties |
| 03/22/2001 | WO2001019776A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 03/22/2001 | WO2001019542A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 03/22/2001 | WO2001019397A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | WO2001019396A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 03/22/2001 | WO2001019381A2 An antioxidant preparation based on plant extracts for the treatment of circulation and chronic degenerative problems and of hypertension |
| 03/22/2001 | WO2001019376A2 METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS |
| 03/22/2001 | WO2001019369A1 Use of thienopyrimidines |
| 03/22/2001 | WO2001019361A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 03/22/2001 | WO2001019351A1 Plastic films, especially for use in a dermal or transdermal therapeutic system |
| 03/22/2001 | WO2001019348A1 Stabilization of enalapril maleate with maleic acid |
| 03/22/2001 | WO2001019347A1 Vascular coating composition |
| 03/22/2001 | WO2001019341A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 03/22/2001 | WO2001019336A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 03/22/2001 | WO2001019334A2 Pharmaceutical solutions of levosimendan |
| 03/22/2001 | WO2001019320A2 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | WO2001019182A1 Nuclear transfer with selected donor cells |
| 03/22/2001 | WO2001019161A2 ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR-β EXPRESSION |
| 03/22/2001 | WO2001019158A2 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems |
| 03/22/2001 | WO2000078341A8 A method for the prophylaxis and/or treatment of medical disorders |
| 03/22/2001 | WO2000073323A3 Adam polynucleotides and polypeptides |
| 03/22/2001 | WO2000059899A8 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 03/22/2001 | WO2000055318A3 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 03/22/2001 | WO2000055155A3 Heterocyclic compounds as adenosine deaminase inhibitors |
| 03/22/2001 | WO2000040612A9 Insulin-like growth factor (igf) i mutant variants |
| 03/22/2001 | WO2000040576A3 Thiopyran compounds as inhibitors of mmp |
| 03/22/2001 | WO2000018421A9 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 03/22/2001 | WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors |
| 03/22/2001 | DE19944604A1 Aminderivate Amine derivatives |
| 03/22/2001 | DE10036855A1 Neue kristalline Form von 6-Hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophenhydrochlorid New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride |
| 03/22/2001 | CA2393896A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | CA2387123A1 Use of thienopyrimidines |
| 03/22/2001 | CA2386525A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 03/22/2001 | CA2385769A1 Kinase inhibitors as therapeutic agents |
| 03/22/2001 | CA2385747A1 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | CA2384783A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | CA2384733A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | CA2384715A1 Prostaglandin derivatives |
| 03/22/2001 | CA2384324A1 Proteins associated with cell differentiation |
| 03/22/2001 | CA2384247A1 Azacycloalkanone serine protease inhibitors |
| 03/22/2001 | CA2383402A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 03/22/2001 | CA2383177A1 Human g-protein coupled receptor |
| 03/22/2001 | CA2382683A1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-¬4-(2-amin-1-yl-ethoxy)-benzyl|-1h-indol-5-ols |
| 03/22/2001 | CA2382633A1 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | CA2381006A1 Antisense modulation of transforming growth factor-.beta. expression |
| 03/22/2001 | CA2350675A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 03/21/2001 | EP1085089A2 Human cyclic nucleotide phosphodiesterase |
| 03/21/2001 | EP1084235A1 Human protein c polypeptide |
| 03/21/2001 | EP1084125A1 Condensed thienopyrimidines with phosphodiesterase-v inhibiting action |
| 03/21/2001 | EP1084123A1 Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect |
| 03/21/2001 | EP1084109A1 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 03/21/2001 | EP1084104A1 Nitric oxide synthase inhibitors |
| 03/21/2001 | EP1084103A1 New 3-aryl-2-hydroxypropionic acid derivative (i) |
| 03/21/2001 | EP1084101A1 New 3-aryl-2-hydroxypropionic acid derivative iii |
| 03/21/2001 | EP1083931A1 Stabilization of compositions containing ace inhibitors using magnesium oxide |
| 03/21/2001 | EP1083928A1 Method of inhibiting angiogenesis and tumor growth and preventing tumor growth and metastases |
| 03/21/2001 | EP1083921A1 Novel leukotriene receptor antagonists and their uses |
| 03/21/2001 | EP1083917A1 Novel analgesic agents |
| 03/21/2001 | EP1083909A1 hCEPR RECEPTOR |
| 03/21/2001 | EP1083905A2 Selective estrogen receptor modulator in combination with dehydroepiandrosterone (dhea) or analogues |
| 03/21/2001 | EP1083904A2 Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol |
| 03/21/2001 | EP1083903A1 Bridged indenopyrrolocarbazoles |
| 03/21/2001 | EP1083900A2 Topical administration of oxazolidinones for transdermal delivery |
| 03/21/2001 | EP1083893A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the d 1? receptors |
| 03/21/2001 | EP1083891A1 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 03/21/2001 | EP1083889A2 Method for treating neurodegenerative disorders |
| 03/21/2001 | EP1083888A1 MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS |
| 03/21/2001 | EP0681569B1 Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| 03/21/2001 | CN1288470A Synthetic polysaccharides, their method of prodn. and pharmaceutical compositions contg. same |
| 03/21/2001 | CN1288464A 4-(2-keto-1-benzimidazolynyl) pipeidine compounds as ORL-1 receptor |
| 03/21/2001 | CN1288382A Sea cucumber carotenoid lipid fraction products and method of use |
| 03/21/2001 | CN1288378A Celecoxib compositions |
| 03/21/2001 | CN1288007A 6-carbonyl-3-(4-[2-(pierid-1-yl)elhoyl]phenoxy)-2(4-methoxylphenyl) benzo[b]thiophene salt crystal |